'For
the quarter ending Dec 2023, consolidated Net sales (including other operating income) of Torrent Pharmaceuticals has increased 9.67% to Rs 2732 crore compared to quarter ended Dec 2022. Operating profit margin has jumped from 29.06% to 31.81%, leading to 20.03% rise in operating profit to Rs 869.00 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 14.22% to 13.83%. Purchase of finished goods cost fell from 14.22% to 11.93%. Employee cost increased from 17.19% to 18.10%. Other expenses fell from 24.95% to 24.44%. Other income fell 230% to Rs -33 crore. PBIDT rose 17.09% to Rs 836 crore. Provision for interest fell 21.57% to Rs 80 crore.
PBDT rose 23.53% to Rs 756 crore. Provision for depreciation rose 10.36% to Rs 213 crore.
Profit before tax grew 29.59% to Rs 543.00 crore. Share ...
Pleaselogin & subscribe to view the full report.
More Reports
-
Revenue up 11% YoY to Rs 33562.9 crore in Q2FY2025
-
(18-Nov-2024)
Bharat Forge
-
-
|
|